Identifying genes that influence neurodegeneration in Alzheimer's and related diseases
Official title: A multiplexable in vivo perturbation toolkit to identify genes affecting neurodegeneration in a model of synucleinopathy
Funded at Columbia University Health Sciences · NIH-11082857 · Data updated 2026-11-12
This study is looking at how certain genes might play a role in brain cell loss in diseases like Alzheimer's and Parkinson's, using mice to find clues that could help develop new treatments for these conditions.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Columbia University Health Sciences NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | September 30, 2023 |
| Project end | September 29, 2025 |
| Funding year | 2024 |
| Award (this year) | $101,927 |
| NIH project number | 3R21AG085144-01S1 |
| Project ID | NIH-11082857 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with Alzheimer's disease, Parkinson's disease with dementia, or dementia with Lewy bodies.
✕Less likely to help
Patients with neurodegenerative disorders unrelated to synucleinopathy may not benefit from this research.
What this research studies
This research investigates the genetic factors that contribute to neurodegeneration in conditions like Alzheimer's disease and Parkinson's disease with dementia. Using advanced CRISPR technology, the study aims to identify specific genes that affect neuronal loss and resilience in a mouse model of synucleinopathy. By profiling the genetic makeup of neurons, researchers hope to uncover potential therapeutic targets and biomarkers that could lead to new treatments for these debilitating diseases.
Why it matters
Potential benefit: If successful, this research could lead to the development of new therapies that slow down or prevent neurodegeneration in patients with Alzheimer's and related disorders.
How similar studies have gone: Previous research using CRISPR technology has shown promise in identifying genetic factors in neurodegenerative diseases, suggesting that this approach could yield valuable insights.
Where this research is happening
-
Columbia University Health Sciences
New York, United States Active
Researchers
- Principal investigator: Przedborski, Serge E — Columbia University Health Sciences
- Study coordinator: Przedborski, Serge E
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.